APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-08-21

Price

$134.75

+0.00%

This is the 2026-08-21 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score11.0Top Tier

Signals6/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.8xvs 20d avg

Analysis

Apogee Therapeutics is exhibiting textbook merger arbitrage price action following AbbVie's definitive agreement to acquire the company for $135.11 per share in cash. The exceptionally low realized volatility of 1.6% and technical signals like QUIET_STORM and PERFECT_STACK reflect institutional arbitrageurs passively absorbing shares to capture the remaining ~0.26% spread. Furthermore, the current RISK_ON macro regime, highlighted by robust Treasury liquidity and historically tight high-yield credit spreads (0.82%), provides immense structural confidence that financing or systemic shocks will not derail the anticipated Q3 2026 close.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKSELLER FATIGUE

Key Takeaways

Actionable Thesis: APGE is a high-probability, low-risk merger arbitrage play trading at a ~0.26% discount to AbbVie's $135.11 cash offer, offering a safe haven for capital.
Key Risk: Regulatory pushback from the FTC regarding AbbVie's consolidation of the immunology market is the primary, albeit remote, tail risk.
What to Watch: Monitor the $134.09 support level for any signs of institutional distribution, and track regulatory updates leading into the Q3 2026 close.

← Back to 2026-08-21 View Full APGE History →Yahoo Finance &nearr;